about
Adoptive T-cell therapy for LeukemiaPR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome.Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data.Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivoCathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.Immunotherapy of AML.Vaccines as consolidation therapy for myeloid leukemia.Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.Cancer immunotherapies, their safety and toxicity.Immune rage against MAGE unleashed.Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cellsNeutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.Immune checkpoints: A therapeutic target in triple negative breast cancerOptimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation.Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft modelImmune aspects of the breast tumor microenvironment.Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANEuPA and uPAR contribute to NK cell invasion through the extracellular matrix.Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Fucosylation enhances activity of cytotoxic T lymphocytes against breast cancer.Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases.Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasionA novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicinIL-2-mediated upregulation of uPA and uPAR in natural killer cellsClinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanomaRhabdomyolysis after ingestion of "foxy," a hallucinogenic tryptamine derivativeMembrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation
P50
Q27006934-6347EA84-B1DF-4373-8924-C57FE067D0A3Q33644438-3B9109D6-1306-4DE2-9D9F-3B0B0751A332Q33644438-AC3BAB4D-364E-485E-BFAB-71C6E1076347Q33772415-64DB7121-5B88-456D-85B3-E18AAA61C4C0Q33905443-3E73C413-95B7-45FB-BCF2-538FA8095A27Q33999284-4571BD7A-67EC-4E88-A2E6-A16B030426F6Q35060682-592E0240-7FF2-4A6C-80D1-6481CCA33AB0Q35129248-EB56956D-14F8-4E62-843C-3CBF04695F38Q36157233-D4E8E4E9-7CAC-4234-994E-E4FD548CA5B5Q36417330-9412C37D-53DF-4787-93C7-C38A15003AA0Q36779819-52ADA612-037A-4D63-8E15-EE17C3F129DDQ37072087-B6CEF28C-DAD3-42F6-B08D-2A42E96865EFQ37561181-C06F1D98-F466-4B21-8CFA-B51B8BF7538DQ37715818-A5619B5A-484B-4EC2-937E-3E273EBFA266Q37842342-A74CE3A4-F767-45A4-80D4-12FFD58AD4C7Q37892580-584FCA5E-C589-4C79-B08A-7893EAC6DD41Q38106230-6AF5EB42-168E-406F-A80E-BC4B829C65CDQ38448219-32C0D794-4B43-4E2E-BDC7-6CA9EE5F777AQ38532002-0215CE5E-0B72-4AF6-BB17-8765F3AC1D89Q38766349-38399594-22F0-441D-AD2A-2731FDAF4805Q38774373-228F69F2-5ECE-43BE-B276-564FE7CDA98AQ39245558-1CB0151B-3801-45A4-8738-1CA6E10A362BQ39422426-59552CDC-AE29-4C2E-AD22-5C5FFD375025Q39631989-7977A19C-7982-4413-9B6E-10B0E9DF04B3Q39632454-C5F0B1BF-E543-4428-B0CB-53F7EA435696Q39655563-A716DD72-A0D6-46F2-8406-EFE5F62C10F1Q41158988-7C00AA4B-A81C-4549-B300-B2985D719076Q41791126-A7A0C260-A8CD-4613-8E03-83C7499CD23BQ41931243-5FA0328C-9909-4649-92F8-862ADACD3B12Q42059781-D364D48E-2D81-4E2E-9F27-C567477009C3Q42826569-BA458685-EA5C-485E-86C5-73D80EF6B215Q43272332-89E84FB0-650E-4A7C-9E7B-DD7ACF486010Q45896384-5DCC688B-38FC-403B-B217-E02E09678C43Q52638390-CF57FC9E-DB6F-4B93-AD30-93696492E5BAQ54798956-39C97843-3EC9-4DC6-A90F-777BF65237B0Q73316776-BFB112FB-4ACA-4B2C-9B39-864C69B71B31Q73656121-C6F09C0B-2D8A-4638-B52A-1E89C88783E4Q77757653-AFE62C12-C3CD-4C62-BCD8-90A7852D0DF5Q80341146-B9E6F144-2A0E-4A28-B127-1758E0A38EE8Q83147073-0ACEA68D-69E9-4246-A134-8CAEF5583867
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gheath Alatrash
@ast
Gheath Alatrash
@en
Gheath Alatrash
@es
Gheath Alatrash
@nl
Gheath Alatrash
@sl
type
label
Gheath Alatrash
@ast
Gheath Alatrash
@en
Gheath Alatrash
@es
Gheath Alatrash
@nl
Gheath Alatrash
@sl
prefLabel
Gheath Alatrash
@ast
Gheath Alatrash
@en
Gheath Alatrash
@es
Gheath Alatrash
@nl
Gheath Alatrash
@sl
P106
P31
P496
0000-0002-7648-4377